MiMedx Group (MDXG) Stock Price, News & Analysis

Company Overview

MiMedx Group, Inc. is a biotechnology company that develops and markets regenerative biologic products derived from human placental tissue. Its products are designed to support the body’s natural healing processes and are used by healthcare professionals in wound care, surgical applications, and musculoskeletal treatment.

The company’s portfolio includes dehydrated human amnion/chorion membrane allografts, including EPIFIX, AMNIOFIX, and AMNIOCORD. These products are used in applications such as chronic wound management, tissue repair, and protection of soft tissue. MiMedx also conducts research and development intended to expand the use of placental tissue-based products in additional clinical settings.

Founded in 2008 and headquartered in Marietta, Georgia, MiMedx primarily serves the U.S. healthcare market through relationships with hospitals, physicians, wound-care centers, and other medical providers. The company’s products are regulated as human cells, tissues, and cellular and tissue-based products and are distributed through commercial and clinical channels.

Key Stats

• Today's Range: $4.40 to $4.71
• 50-Day Range: $4.13 to $4.93
• 52-Week Range: $3.03 to $7.97
• Volume: 1.46 million shs
• Average Volume: 1.09 million shs
• Market Capitalization: $680.70 million
• P/E Ratio: 116.78
• Dividend Yield: N/A
• Price Target: $8.57
• Consensus Rating: Moderate Buy

MiMedx Group Stock Analysis - MarketRank™

MiMedx Group scored higher than 48% of companies evaluated by MarketBeat, and ranked 564th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

MiMedx Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

MiMedx Group has a consensus price target of $8.57, representing about 83.5% upside from its current price of $4.67.

Amount of Analyst Coverage

MiMedx Group has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MiMedx Group are expected to grow in the coming year, from ($0.10) to $0.17 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MiMedx Group is 116.78, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.64.

Price to Earnings Ratio vs. Sector

The P/E ratio of MiMedx Group is 116.78, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.82.

Price to Book Value per Share Ratio

MiMedx Group has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.57% of the float of MiMedx Group has been sold short.

Short Interest Ratio / Days to Cover

MiMedx Group has a short interest ratio ("days to cover") of 10.87, which indicates bearish sentiment.

Change versus previous month

Short interest in MiMedx Group has recently increased by 14.66%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MiMedx Group does not currently pay a dividend.

Dividend Growth

MiMedx Group does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.60

News Sentiment

MiMedx Group has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for MiMedx Group this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MiMedx Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.50% of the stock of MiMedx Group is held by insiders.

Percentage Held by Institutions

79.15% of the stock of MiMedx Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 9/27/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MDXG
• CIK: 1376339
• Web: www.mimedx.com
• Phone: (770) 651-9100
• Fax: 678-384-6741
• Employees: 808
• Year Founded: 2008

Price Target and Rating

• Average Price Target for MiMedx Group: $8.57
• High Price Target: $10.00
• Low Price Target: $6.00
• Potential Upside/Downside: +83.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.04
• Trailing P/E Ratio: 116.78
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $48.58 million
• Net Margins: 1.76%
• Pretax Margin: 3.25%
• Return on Equity: 12.09%
• Return on Assets: 9.22%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 5.33
• Quick Ratio: 4.79

Sales & Book Value

• Annual Sales: $355.17 million
• Price / Sales: 1.92
• Cash Flow: $0.55 per share
• Price / Cash Flow: 8.43
• Book Value: $1.73 per share
• Price / Book: 2.70

Miscellaneous

• Outstanding Shares: 145,760,000
• Free Float: 142,116,000
• Market Cap: $680.70 million
• Optionable: Optionable
• Beta: 1.43